- Home
- NAAS vs IGC Comparison
NAAS vs IGC Comparison
Compare NAAS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | IGC |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 28.5M |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NAAS | IGC |
|---|---|---|
| Price | $2.04 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 4.8K | ★ 333.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | $378.49 | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.24 |
| 52 Week High | $4.54 | $0.50 |
Technical Indicators
Market Signals| Indicator | NAAS | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 31.52 | 55.03 |
| Support Level | $0.55 | N/A |
| Resistance Level | $3.77 | $0.32 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 30.00 | 66.67 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.